A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (ECOG 1208)
What is the purpose of this trial?
To compare Progression-Free Survival (PFS) of chemoembolization alone to sorafenib in combination with chemoembolization.
- 18 Years and older
- Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
- Last Updated:
- Study HIC#: